In the original article, there was an error. For the sentence “NMDA receptor antagonists (AM-101) have been discontinued in phase III for not meeting endpoints (van de Heyning et al., 2014)” there was a typographical error (phase III should have been phase II). In addition, it was brought to our attention that clinical trials for AM-101 are ongoing.
A correction has been made to section 6. Treatment Development, Subsection 6.4. Pharmacology-Based Interventions, paragraph 1. The corrected paragraph is below.
A wide variety of therapeutic drugs have been used to relieve tinnitus (Elgoyhen and Langguth, 2010). For acute tinnitus, a dose-dependent reduction in tinnitus intensity was observed with intravenous lidocaine (Trellakis et al., 2006). However, its use is controversial due to its short-lasting response, its potentially life threatening arrhythmogenic side effects, and the low bioavailability of its oral form (Israel et al., 1982; Trellakis et al., 2007; Gil-Gouveia and Goadsby, 2009). A potential goal of pharmacologic tinnitus research could be to identify the mechanism by which lidocaine interferes with tinnitus and mimic this effect using a drug with better tolerance that can be orally administered. For chronic tinnitus, the off-label use of medicines like betahistine (Hall et al., 2018d), anticonvulsants (Hoekstra et al., 2011), and glutamate receptor antagonists have shown little or no effect in clinical trials. Prescription of antidepressants and benzodiazepines is limited to tinnitus-associated comorbidities such as depression, insomnia and anxiety (Langguth et al., 2019). Moreover, three clinical research programs, in the last few years, were discontinued in phase II and III. AMPA antagonist selurampanel (BGG492) has not resulted in a new compound (Cederroth et al., 2018). NMDA receptor antagonists (AM-101) did not meet the primary endpoint of improving minimum masking level in acute tinnitus in a phase II clinical trial but showed improvement for tinnitus loudness, annoyance, sleep difficulties, and tinnitus impact in patients with tinnitus after noise trauma or otitis media (van de Heyning et al., 2014). Many other treatments decreasing tinnitus percept or targeting central auditory processing pathways are at a preclinical phase (Schilder et al., 2019). The modulator of voltage-gated potassium channels (Kv3.1) (AUT00063) was not effective in alleviating tinnitus symptoms (Hall et al., 2019b).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
CederrothC. R.Dyhrfjeld-JohnsenJ.LangguthB. (2018). An update: emerging drugs for tinnitus. Expert Opin. Emerg. Drugs23, 251?260. 10.1080/14728214.2018.1555240
2
ElgoyhenA. B.LangguthB. (2010). Pharmacological approaches to the treatment of tinnitus. Drug Discov. Today15, 300?305. 10.1016/j.drudis.2009.11.003
3
Gil-GouveiaR.GoadsbyP. (2009). Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review. Cephalalgia29, 496?508. 10.1111/j.1468-2982.2008.01800.x
4
HallD. A.RayJ.WatsonJ.SharmanA.HutchisonJ.HarrisP.et al. (2019b). A balanced randomised placebo controlled blinded phase iia multi-centre study to investigate the efficacy and safety of aut00063 versus placebo in subjective tinnitus: the quiet-1 trial. Hear. Res. 377, 153?166. 10.1016/j.heares.2019.03.018
5
HallD. A.WegnerI.SmitA. L.McFerranD.StegemanI. (2018d). Betahistine for tinnitus. Cochrane Database Syst. Rev. 2018:CD013093. 10.1002/14651858.CD013093.pub2
6
HoekstraC. E.RynjaS. P.van ZantenG. A.RoversM. M. (2011). Anticonvulsants for tinnitus. Cochrane Database Syst. Rev. 7:CD007960. 10.1002/14651858.CD007960.pub2
7
IsraelJ. M.ConnellyJ. S.McTigueS. T.BrummettR. E.BrownJ. (1982). Lidocaine in the treatment of tinnitus aurium: a double-blind study. Arch. Otolaryngol. 108, 471–473.
8
LangguthB.ElgoyhenA. B.CederrothC. R. (2019). Therapeutic approaches to the treatment of tinnitus. Annu. Rev. Pharmacol. Toxicol. 59, 291?313. 10.1146/annurev-pharmtox-010818-021556
9
SchilderA. G.SuM. P.BlackshawH.LustigL.StaeckerH.LenarzT.et al. (2019). Hearing protection, restoration, and regeneration: an overview of emerging therapeutics for inner ear and central hearing disorders. Otol. Neurotol. 40, 559?570. 10.1097/MAO.0000000000002194
10
TrellakisS.BenzenbergD.UrbanB. W.FriederichP. (2006). Differential lidocaine sensitivity of human voltage-gated potassium channels relevant to the auditory system. Otol. Neurotol. 27, 117?123. 10.1097/01.mao.0000186443.11832.8a
11
TrellakisS.LautermannJ.LehnerdtG. (2007). Lidocaine: neurobiological targets and effects on the auditory system. Prog. Brain Res. 166, 303?322. 10.1016/S0079-6123(07)66028-2
12
van de HeyningP.MuehlmeierG.CoxT.LisowskaG.MaierH.MorawskiK.et al. (2014). Efficacy and safety of am-101 in the treatment of acute inner ear tinnitus a double-blind, randomized, placebo-controlled phase II study. Otol. Neurotol. 35:589. 10.1097/MAO.0000000000000268
Summary
Keywords
tinnitus, review, heterogeneity, standardization, interdisciplinary collaborations, big data, treatment development
Citation
Simoes JP, Daoud E, Shabbir M, Amanat S, Assouly K, Biswas R, Casolani C, Dode A, Enzler F, Jacquemin L, Joergensen M, Kok T, Liyanage N, Lourenco M, Makani P, Mehdi M, Ramadhani AL, Riha C, Santacruz JL, Schiller A, Schoisswohl S, Trpchevska N and Genitsaridi E (2021) Corrigendum: Multidisciplinary Tinnitus Research: Challenges and Future Directions From the Perspective of Early Stage Researchers. Front. Aging Neurosci. 13:730758. doi: 10.3389/fnagi.2021.730758
Received
25 June 2021
Accepted
02 July 2021
Published
09 August 2021
Volume
13 - 2021
Edited and reviewed by
Daniel Ortuño-Sahagún, University of Guadalajara, Mexico
Updates
Copyright
© 2021 Simoes, Daoud, Shabbir, Amanat, Assouly, Biswas, Casolani, Dode, Enzler, Jacquemin, Joergensen, Kok, Liyanage, Lourenco, Makani, Mehdi, Ramadhani, Riha, Santacruz, Schiller, Schoisswohl, Trpchevska and Genitsaridi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eleni Genitsaridi eleni.genitsaridi@nottingham.ac.ukJorge Piano Simoes jorge.simoes@ukr.deMaryam Shabbir maryam.shabbir@nottingham.ac.ukElza Daoud elzadaoud@gmail.com
†These authors have contributed equally to this work and share first and senior authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.